Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma
2. B-cell acute lymphoblastic leukemia or a B-cell lymphoma
3. With gamma globulins \<4g/L at the time of screening
4. Receiving CD19-targeted autologous CAR-T cells (with AMM in their indication)
5. Patients with childbearing potential\* should have reliable contraception for the all duration of the study and another 12 months after CAR-T infusion.
6. Contraceptive measures for concerned patients
7. Informed consent signed by patient or legal representatives
You may not be if
1. Any medical history of intolerance to intravenous immunoglobulin
2. With renal failure calculated glomerular filtrate rate \<30 mL / min;
3. With hepatic failure or hepatitis or bilirubin\> 3 times the upper limit of normal, Serum ALT/AST \>=5N
4. With existing serious acute infection
5. Contraindication to immunoglobulin or to prophylactic antibiotherapy administered in this clinical trial
6. No health insurance coverage
7. Females who are pregnant or breastfeeding
8. Participation in another interventional study or being
Clareo Health | Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell Lymphoma
